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Abstract: Highly pathogenic avian influenza virus (HPAIV) of subtype H5N1 causes a 
devastating disease in poultry but when it accidentally infects humans it can cause death. 
Therefore, decrease the incidence of H5N1 in humans needs to focus on prevention and 
control of poultry infections. Conventional control strategies in poultry based on 
surveillance, stamping out, movement restriction and enforcement of biosecurity measures 
did not prevent the virus spreading, particularly in developing countries. Several challenges 
limit efficiency of the vaccines to prevent outbreaks of HPAIV H5N1 in endemic 
countries. Alternative and complementary approaches to reduce the current burden of 
H5N1 epidemics in poultry should be encouraged. The use of antiviral chemotherapy and 
natural compounds, avian-cytokines, RNA interference, genetic breeding and/or 
development of transgenic poultry warrant further evaluation as integrated intervention 
strategies for control of HPAIV H5N1 in poultry. 
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Abbreviations 
AIV= avian influenza virus, ChIFN-α = chicken interferon alpha, ChIL = chicken interleukin,  
ECE= embryonated chicken eggs, HA = hemagglutinin, HPAIV = highly pathogenic avian influenza 
virus, IFN = interferon, LPAIV = low pathogenic avian influenza virus, Mx = myxovirus,  
NA = neuraminidase, NAIs = neuraminidase inhibitors, rFPV = recombinant fowl pox virus,  
RIG-I = retinoic acid-inducible gene I, RNA = ribonucleic acid, RNAi = RNA interference,  
siRNA = short-interfering RNA, SPF = specific pathogen free, TLR = Toll-like receptors 
1. Introduction 
Influenza A virus, the only orthomyxovirus known to infect birds, are negative-sense,  
single-stranded, enveloped viruses contain genomes composed of eight separate ribonucleic acid 
(RNA) segments encode for at least 11 viral proteins. Two surface glycoproteins; hemagglutinin (HA) 
and neuraminidase (NA) are playing a vital role in attachment and release of the virus, respectively [1]. 
The 17 HA and 10 NA subtypes of avian influenza viruses (AIV) are classified according to their 
pathogenicity for poultry into low pathogenic AIV (LPAIV) result in mild or asymptomatic infections 
and highly pathogenic AIV (HPAIV) causing up to 100% morbidity and mortality [2,3]. To date, some 
strains of H5 or H7 subtypes fulfilled the defined criteria of high pathogenicity which potentially 
evolve from low virulent precursors [4]. Constant genetic and antigenic variation of AIV is an 
intriguing feature for continuous evolution of the virus in nature [5]. Gradual antigenic changes due to 
acquisition of point mutations known as “antigenic drift” are commonly regarded to be the driving 
mechanism for influenza virus epidemics from one year to the next. However, possible “antigenic shift 
or reassortment” of influenza virus occurs by exchange genes from different subtypes is relatively 
infrequent, however it results in severe pandemics [6]. 
HPAIV H5N1 is responsible for magnificent economic losses in poultry industry and poses a 
serious threat to public health [7,8]. Measures to control the virus in domestic poultry are the first step 
to decrease risks of human infections [9,10]. Enhanced biosecurity measures, surveillance, stamping 
out and movement restriction as basic principles for control of HPAIV H5N1 epidemics in poultry [11] 
has not prevented the spread of the virus since 1997 [12,13]. Recently, vaccines have been introduced 
in some developing countries as a major control tool to reduce the overwhelming socioeconomic 
impact of HPAI H5N1 outbreaks in poultry [13]. Different types of inactivated vaccines and to lesser 
extent recombinant live virus vaccines are already in use that decrease shedding of the virus, 
morbidity, mortality, transmissibility, increase resistance to infection, lower virus replication and limit 
decrease in egg production [2,14].  
Nevertheless, several challenges facing the efficiency of the vaccine to control the HPAIV H5N1 
outbreaks have been reported: (1) Vaccine is HA subtype specific and in some regions where multiple 
subtypes are co-circulating (i.e., H5, H7 and H9), vaccination against multiple HA subtypes is 
required [15]. (2) Vaccine-induced antibodies hinder routine serological surveillance and differentiation 
of infected birds from vaccinated ones requires more advanced diagnostic strategies [16]. 
(3) Vaccination may prevent the clinical disease but can’t prevent the infection of vaccinated birds, 
thus continuous “silent” circulation of the virus in vaccinated birds poses a potential risk of virus 
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spread among poultry flocks and spillover to humans [17–19]. (4) Immune pressure induced by 
vaccination on the circulating virus increases the evolution rate of the virus and accelerates the viral 
antigenic drift to evade the host-immune response [20–24]. (5) After emergence of antigenic variants, 
the vaccine becomes useless and/or inefficient to protect the birds and periodical update of the vaccine 
is required [20,25–28]. (6) Vaccine-induced immunity usually peaks three to four weeks after 
vaccination and duration of protection following immunization remains to be elucidated [29]. 
(7) Maternally acquired immunity induced by vaccination of breeder flocks could interfere with 
vaccination of young birds [30–34]. (8) Other domestic poultry (i.e., ducks, geese, turkeys), zoo and/or 
exotic birds even within the same species (i.e., Muscovy vs. Pekin ducks) respond differently to 
vaccination which have not yet been fully investigated compared to chickens [35–42]. (9) Concomitant 
or prior infection with immunosuppressive pathogens or ingestion of mycotoxins can inhibit the 
immune response of AIV-vaccinated birds [43–46]. (10) And last but not least, factors related to 
vaccine manufacturing, quality, identity of vaccine strain, improper handling and/or administration can 
be decisive for efficiency of any AIV vaccine [2,29].  
Therefore, presence of new alternative and complementary strategies target different AIV 
serotypes/subtypes/drift-variants should be encouraged. This review aims to give an insight into possible 
alternative approaches for control of AIV in poultry particularly against the HPAI H5N1 subtype. 
2. Antivirals 
2.1. Chemotherapy 
The use of chemotherapeutic agents for control of AIV in poultry was concurrently studied just 
after discovering their anti-microbial effects [47,48]. However, during the last three decades more 
attention was paid to the commonly used antivirals, M2 blocker and neuraminidase inhibitors (NAIs), 
in control of human influenza viruses to be used in eradication of AIV in poultry.  
2.1.1. M2 Blockers (Adamantanes)  
Amantadine hydrochloride and rimantadine are two M2 blockers which interrupt virus life cycle by 
blocking the influx of hydrogen ions through the M2 ion-channel protein and prevent uncoating of the 
virus in infected host-cells [49–51]. The prophylactic activity of amantadine in poultry was firstly 
studied by Lang et al. [52] in experimentally infected turkeys with an HPAIV H5N9 isolated in 1966 
from Ontario, Canada. Optimum prophylaxis was obtained only when amantadine was administered in 
an adequate, uninterrupted and sustained amount from at least 2 days pre-infection to 23 days 
post-infection. During H5N2 outbreaks in Pennsylvania, USA in early 1980s, one of control proposals 
was the use of amantadine as a therapeutic and/or prophylactic approach. Under experimental 
condition, amantadine given in drinking water was efficacious to decrease morbidity, mortality, 
transmissibility and limit decrease in egg production [53,54]. Nonetheless, all recovered birds were 
susceptible to reinfection [52,54–56] and subclinical infection was reported in most of treated 
birds [52]. Importantly, amantadine lost its effectiveness as amantadine-resistant mutants emerged  
within 2–3 days of treatment and killed all in-contact chickens. Amantadine-resistant strains were 
irreversible, stable and transmissible with pathogenic potential comparable to the wild-type virus. Even 
Viruses 2012, 4        
 
more, the resistant mutants replaced the wild-type virus and became dominant [55–57]. It is worth 
pointing out that several subtypes of AIV including the HPAIV H5N1 that currently circulate in both 
humans and birds around the world are mostly resistant to amantadine [58–65]. Since the late 1990s, 
positive selection of amantadine-resistant HPAI H5N1 viruses in poultry in China has been proven to 
be increased due to extensive illegal application of the relatively inexpensive amantadine by some 
farmers to control HPAIV H5N1 (and LPAIV H9N2) infections in chickens [62,66–69]. Hence, rapid 
selection of amantadine-resistant variants threatens the effective use of the drug for control of human 
influenza epidemics and/or pandemics [70], therefore the extra-label use of amantadine in poultry was 
banned by all concerned international organizations [71,72]. The second M2 blocker is rimantadine. 
Because of the unavailability of rimantadine in most countries, its use in poultry is not reported until 
now in the field. However, Webster et al. [73] mentioned that rimantadine administered in drinking 
water was efficacious against HPAIV H5N2 infection in experimentally infected chickens. 
Nonetheless, the emergence of rimantadine-resistant variants was comparable to amantadine. 
2.1.2. Neuraminidase Inhibitors (NAIs) 
So far, there are two main NAIs, oseltamivir (Tamiflu®) and zanamivir (Relenza®) have been 
licensed for influenza treatment in human in several countries [74]. When exposed to NAIs, influenza 
virions aggregate on the host cell surface preventing their release and allow the host immune system to 
eliminate the virus [75,76]. In the early 2000s, oseltamivir was discovered as a potent and selective 
inhibitor of the NA enzyme of influenza viruses [50]. It is currently the drug of choice for the 
treatment of influenza virus infections in human and being stockpiled in many countries in anticipation 
of a pandemic [77]. Generally, AIV including H5N1 are sensitive to oseltamivir [78] and a small 
number of H5N1 strains isolated from avian and human origin have been reported to exhibit resistance 
to oseltamivir [79–84]. Oral application of oseltamivir via drinking water reduced the morbidity, 
mortality, virus excretion and chicken-to-chicken transmission in HPAIV H5N2 experimentally 
infected chickens [85]. Oseltamivir was non-toxic for chicken embryos and prevented the replication 
of an HPAIV H7N1 in inoculated eggs [86]. An effective prophylactic administration of oseltamivir 
in experimentally infected chickens and ducks with LPAI H9N2 and H6N2 viruses was also 
reported [87]. Although it is very plausible that oseltamivir-resistance mutants emerge after application 
in poultry, however none of the few studies conducted to evaluate efficacy of oseltamivir in avian 
species reported emergence of resistant strains. In nature, oseltamivir-resistant H5N1 viruses isolated 
from domestic and wild birds emerged probably due to spontaneous mutations rather than exposure to 
oseltamivir [80,88–90]. Administration of oseltamivir during an outbreak in commercial flocks is 
extremely expensive but it could be useful to protect valuable birds [86,87]. On the other hand, 
zanamivir is currently approved in 19 countries for the treatment and prophylaxis of human 
influenza [50]. Although, development of zanamivir-resistance in poultry is rare [91], it is not effective 
in preventing a severe outcome and chicken-to-chicken transmission of an HPAIV H5N2 in 
experimental chickens [85].  
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2.2. Natural Antivirals 
2.2.1. Herbs 
Unlimited herbs products contain polyphenols, flavonoids, alkaloids or lignans, mostly from 
traditional Chinese medicine, offer promise as adjuncts or alternatives to the current anti-influenza 
chemotherapy [92,93]. Generally, complementary medicine for treating or preventing influenza or 
influenza-like illness in human seems to be cultural practice differs from nation to nation [94–96]. 
Innumerable herbs species with potential inhibitory effects on replication of influenza viruses using 
in-vitro cell culture methods and embryonated eggs or in-vivo mouse models were frequently 
described [97–123].  
In poultry, antiviral and immunoadjuvant effects of several plants and/or its derivatives have been 
investigated. In addition to its antiviral activity, these extracts often have anti-bacterial, anti-fungal, 
anti-inflammatory, anti-oxidant and/or analgesic properties which may provide alternative natural 
broad-spectrum therapy for control of AIV in poultry farms [124–127]. Sood et al. [127] found that 
Eugenia jambolana extracts had 100% virucidal activity against HPAIV H5N1 in tissue culture and 
in-ovo inoculated chicken embryonated eggs (ECE). Menthol, eucalyptol and ormosinine probably 
have inhibitory effect on H5 viruses due to strong interactions ability with the viral HA protein [128]. 
NAS preparation, a Chinese herbal medicine, prevented H9N2 virus-induced clinical signs in treated 
chickens; however transmission of the virus to untreated chickens was not interrupted [129]. 
Likewise, eucalyptus and peppermint essential oils preparations protected broilers against H9N2 virus 
infections [130,131]. Moreover, application of lyophilized green tea by-product extracts namely 
catechins in feed or drinking water reduced H9N2 virus replication and excretion in experimentally 
infected chickens in a dose-dependent manner [132]. In addition, green tea extract was comparable to 
amantadine in protection of chicken embryos against H7N3 subtype [120]. Catechins alter the 
infectivity of influenza viruses probably not only by direct interaction with viral HA but also by 
inhibition of viral RNA synthesis in cell culture [133]. Furthermore, Liu et al. [134] found that 
statin/caffeine combination was as effective as oseltamivir in reduction HPAIV H5N1-induced lung 
damage and viral replication in mice. 
The immunoadjuvant effect of some herbal extracts as feed additives on the humoral immune 
response induced by inactivated AIV vaccination in poultry has been studied. Oral administration 
of ginseng stem-and-leaf saponins in drinking water or Hypericum perforatum L. as a dietary 
supplement significantly enhanced serum antibody response to inactivated H5N1 or H9N2 vaccines in 
chickens [135–137]. The Cochinchina momordica seed extract, Chinese medicine plant, when 
combined with an inactivated H5N1 vaccine as adjuvant increased significantly the immune response 
and daily weight gain of two weeks old chickens [138]. On the contrary, herbal extracts of Radix 
astragali, Radix codonopis, Herba epimedii and Radix glycyrrizae in drinking water did not improve 
chicken immune response to H5-AIV vaccination [139], likewise diet supplementation with fresh 
garlic powder had no effect on the humoral immune response of chickens vaccinated with an 
inactivated H9N2 vaccine [140].  
Yet, some derivatives (i.e., ginseng saponins) require four to six years to harvest and is very 
expensive on the market [135]. Methods of the extraction and preparation of the crude extracts and its 
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purity greatly influence the inhibition activity of some herbs against AIV [132,133]. Moreover, 
batch-to-batch variations due to variable growth conditions at the plantations have been considered a 
limiting factor for treatment of influenza [124]. Evident that mutation in the H5 gene probably affects 
inhibitor binding of some herbs was reported [128]. In addition, in-vitro experiments and animal 
models to confirm the direct antiviral activities against influenza virus are limited [141]. Moreover, 
comprehensive investigations of herb-drug interactions, potential toxicity, heterogeneity of herbs 
species, plant parts (i.e., aerial vs. root) and biochemical data identifying the active components are 
inadequately described [142].  
2.2.2. Probiotics  
A number of studies have reported the efficacy of probiotic lactic acid bacteria such as 
Streptococcus thermophiles, several Lactobacillus and Bifidobacterium species to enhance the immune 
response and to protect mice against different influenza strains/serotypes [143–152]. Although 
probiotics are widely used in poultry to improve innate and adaptive immunity [153–155], there is a 
paucity of information on its ability to ameliorate AIV infections. Lactobacillus plantarum 
KFCC11389P was as effective as oseltamivir to neutralize the H9N2 virus in ECE and slightly reduced 
amount of tracheal virus excretion in oral-fed experimentally infected chickens [156]. Out of 
220 screened bacterial strains, Seo et al. [157] found that Leuconostoc mesenteroides YML003 had 
highly anti-H9N2 activity in cell culture and ECE. Decrease cloacal excretion of the virus and a 
significant increase in the cytokine IFN-gamma in experimentally infected chickens were observed. 
Ghafoor and co-workers [158] showed that multi-strains commercial probiotic protexin® (various 
Lactobacillus sp., Enterococcus faecium, Bifidobacterium bifidum, Candida pintolepesii and 
Aspergillus oryzae) improved immune response of broiler chickens to H9N2 vaccination and 
prevented the mortality and morbidity. On the other hand, dual use of Lactobacillus spp. or 
Lactococcus lactis as a vector for vaccine production and immunomodulation bacteria has been 
successfully constructed and protected mice against HPAIV H5N1 [159,160], such experiments should 
be evaluated in poultry. 
3. Molecular Approaches for Control of AIV 
3.1. Avian-Cytokines 
Chicken cytokines such as chicken interferon-alpha (ChIFN-α), chicken interleukins (ChIL) and 
Toll-like receptors (TLR) are essential components of chicken’s innate immune system which play a 
vital role against virus infections [15,161–163]. An innovative application of ChIFN-α to antagonize 
AIV infection in poultry through direct oral feeding or drinking water has received more attention than 
other components [164–168]. Sekellick et al. [169] showed that up to 60% of investigated AIV 
population belonged to the HPAI H5N9 subtype were highly sensitive to the inhibitory effects of 
ChIFN-α. Interestingly, both IFN-sensitive and -resistant clones were obtained after passage of the 
resistant clones in the presence of IFN which indicated that resistance to ChIFN-α was transient and 
did not result from stable genetic changes. Xia et al. [170] cloned the ChIFN-α gene from three 
different chicken lines and studied their efficacy against H9N2 viruses in-ovo and in-vivo. Up to 70% 
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of in-ovo treated chicken embryos were protected against H9N2 virus infection in dose dependent 
manner. Moreover, chickens received ChIFN-α by oculonasal inoculation at one day of age were 
protected from death upon H9N2 virus infection given 24 hours later. Findings of Meng and 
co-workers [166] showed that oral administration of exogenous ChIFN-α was effective to prevent and 
treat chickens experimentally infected with an H9N2 virus. It potentially reduced the viral load in 
trachea and resulted in rapid recovery of the body weight gain. In another study, White Leghorn (WL) 
chickens received ChIFN-α in drinking water for 14 successive days augmented detectable humoral 
anti-influenza antibodies after exposure to a low dose of an LPAIV H7N2 infection [164]. Thus, it has 
been suggested that regular water administration of ChIFN-α can create “super-sentinel” chickens to 
detect early infections with few amount of LPAIV [164].  
Furthermore, oral administration of live attenuated Salmonella enterica serovar Typhimurium 
expressing ChIFN-α alone or in combination with ChIL-18 significantly reduced clinical signs induced 
by H9N2 virus and decreased the amount of virus load in cloacal swabs and internal organs [171,172]. 
Likewise, chicken immunized with a recombinant fowl pox virus (rFPV) vaccine expressing both the 
HA gene of H9N2 virus and ChIL-18 survived challenge with an H9N2 virus and did not excrete any 
virus in swab samples and/or internal organs in comparison to non-vaccinated birds [173]. Also, rFPV 
expressing the H5, H7 and ChIL-18 genes produced significantly higher humoral and cellular mediated 
immune response and protected specific pathogen free chickens (SPF) and WL chickens against 
challenge with an HPAIV H5N1. Vaccinated birds had no virus shedding and showed significant 
increase in body weight gain [174]. So far, efficiency of avian-cytokines to limit AIV infection has not 
been adequately studied in other avian species. The duck IL-18 and IL-2 genes had been identified 
and shown to have 85% and 55% nucleotide identity to the chicken equivalents, respectively. 
Intramuscular inoculations of the duck IL-18 or IL-2 enhanced the humoral immune response of ducks 
vaccinated with H5N1 or H9N2 inactivated vaccines, respectively [175,176]. Likewise, the 
recombinant goose IL-2 strengthens goose humoral immune responses after vaccination using H9N2 
inactivated vaccine [177]. 
The TLR-3, TLR-7 and TLR9 are other promising chicken cytokines derivatives that showed 
broad-spectrum anti-influenza virus activity in-vitro and in-ovo [178–181]. Nevertheless, the cost of 
mass production of chicken cytokines is still too high to be applied in large-scale in poultry 
industry [165]. Moreover, protein stability, host-specificity and labor associated with mass 
administration of chicken cytokines under field conditions require significant improvement [172]. 
3.2. RNA Interference (RNAi) 
RNAi is a natural phenomenon used by many organisms as a defense mechanism against foreign 
microbial invasion, including viruses, that able to wreak potential genetic havoc of the susceptible 
host [182]. Short-interfering RNA (siRNA) is approximately 21–25 nucleotides specific for highly 
conserved regions of AIV genomes. It effectively mediates the catalytic degradation of complementary 
viral mRNAs and results in inhibition of a broad spectrum of influenza viruses replication in cell lines, 
chicken embryos and mice just before or after initiation of an infection [183–187]. Tompkins and 
colleagues [188] found that siRNA specific for the NP or PA genes induced full protection of mice 
against lethal challenge with the HPAI H5N1 and H7N7 subtypes and markedly decreased virus titers 
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in lungs. Likewise, prophylactic use of PA-specific siRNA molecule significantly reduced lung H5N1 
virus titers and lethality in infected mice [189]. Moreover, siRNA targeting M2 or NP genes inhibited 
replication of H5N1 and H9N2 viruses in canine cell line and partially protected mice against HPAV 
H5N1 [190]. 
In poultry, Li and others [191] showed that the siRNA targeting NP and/or PA genes inhibited 
protein expression, RNA transcription and multiplication of HPAIV H5N1 in chicken embryo 
fibroblasts and ECE as well as prevented apoptosis of infected cells. Likewise, chicken cell line 
transfected with RNAi molecules specific for the NP or PA of AIV showed decrease the levels of NP 
mRNA and infective titre of an H10N8 quail virus [192]. Also, NP-specific siRNA reduced H5N1 
virus replication in cell culture and ECE [186]. Moreover, siRNA molecules targeting the NP, PA and 
PB1 genes interfered with replication of H1N1 virus in ECE [184].  
In contrast to AIV vaccines, siRNA might not require an intact immune system [193] which is very 
important particularly in developing countries where a number of immunosuppressive agents are 
endemic in poultry. In addition, siRNA molecules targeting the highly conserved regions in influenza 
genome potentially remain effective regardless AIV subtype/serotype variations and despite antigenic 
drift and shift of AIV [193,194]. Moreover, it has also the potential to reduce the emergence of viable 
resistant variants [10], in this regard combinations of siRNA molecules “cocktail” targeting several 
genes/regions may be used simultaneously [195,196]. Furthermore, there is no risk of recombination 
between siRNA nucleotides and circulating influenza viruses, hence siRNA is complementary to the 
influenza virus genome [10]. Moreover, the siRNA dose required for inhibition of AIV is very low 
(sub-nanomoles) [195]. Nevertheless, arise of mutants with the ability to evade the inhibition effect of 
siRNA are not fully excluded [193]. Unfortunately, there is no stretch of conserved nucleotides in the 
NA and HA genes sufficient to generate specific siRNA due to extensive variations in these genes 
among AIV from different species [195]. The siRNA molecules are quickly degraded in-vivo affording 
a transient short-term protection and multiple-dose is required [192]. None of the siRNAs must share 
any sequence identity with the host genome to avoid non-specific RNAi-induced gene silencing 
of the host cells [195,197–199]. Delivery vehicle of siRNA to the site of infection is a major 
constraint [200,201] remained to be investigated on flock-level in poultry. There is accumulating 
evidence that siRNA is efficient to inhibit influenza virus replication in-vitro, however in-vivo studies 
still missing. Research studies focus on mass application of siRNA in poultry as a spray or via 
drinking water are highly recommended [202].  
3.3. Host Genetic Selection 
The host genetics play a pivotal role in susceptibility to influenza including the HPAIV H5N1 
which is frequently studied in mice models as reviewed by Horby et al. [203]. Indeed, the impact of 
host genetic selection on resistance to AIV infections in poultry has not yet been fully determined. The 
on-going H5N1 virus epidemics have raised concerns in respect to influenza-resistant chickens either 
by selective breeding or genetic modification. 
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3.3.1. Natural Resistance 
It has been supposed that fast-growing domestic birds have reduced immune competence against 
several viral diseases and resistant breeds are mostly poor producers [204]. Natural resistance or less 
susceptibility of some species/breeds of birds to AIV is not uncommon. In an experiment, five chicken 
lines were infected with an HPAIV H7N1. Three lines showed high susceptibility to the virus while 
two lines showed some resistance and survived the infection [205]. Swayne et al. [206] observed that 
an LPAIV H4N8 produced more severe lesions in commercial and SPF WL chickens than 
in 5 week-old commercial broiler chickens suggesting that SPF WL chickens are more susceptible than 
broilers to this strain. Thomas et al. [207] suggested that WL chickens may be more susceptible to an 
H3N2 virus of swine origin than White Plymouth Rock broiler-type chickens. On the contrary, severe 
lesions in commercial broiler chickens compared to SPF was observed after experimental infection 
with a Jordanian H9N2 isolate [208]. Some wild duck species, particularly mallards, are more 
resistance to HPAIV H5N1 than others [209]. Conversely, dabbling ducks and white fronted goose 
were more frequently infected with AIV than other wild ducks and geese, respectively [210]. Wood 
ducks were the only species to exhibit illness or death between different species of experimentally 
infected wild ducks in a study conducted by Brown and others [211].  
3.3.1.1. Myxovirus (Mx) Resistance Gene  
Myxovirus resistance gene is an interferon-stimulated gene encodes Mx1 protein that able to 
interfere with AIV replication by inhibiting viral polymerases in the nucleus and by binding viral 
components in the cytoplasm. The role of the Mx gene in resistance against influenza viruses including 
the HPAIV H5N1 in mammals is well defined [212–218]. However, the contribution of avian Mx 
proteins as antiviral elements in AIV infection in birds is contradictory and worth further exploration. 
Although intra- and inter-breed/-species Mx variations have been frequently reported [205,219–226], 
however commercial chicken lines have lower frequencies of the resistant allele compared to the 
indigenous chicken breeds [219,220,227] probably due to intensive modern breeding techniques [228]. 
Duck Mx was the first avian Mx protein to be characterized but no antiviral activity against an HPAIV 
H7N7 when transfected in chicken and mouse cells was obtained [229]. On the contrary, chickens 
have a single Mx1 gene [230] with multiple alleles [220] encoding a deduced protein with 705 amino 
acids in length. Notably, results of anti-influenza activity of the Mx1 protein in chickens are 
contradictory likely due to using variable experimental setups and different AIV strains. Also, a similar 
disparity has been noted between in-vitro and in-vivo experiments [205,231].  
Phenotypic variation in the antiviral activity of Mx gene has been linked to a single amino acid 
substitution of asparagine (Asn) at position 631 in resistant breeds or serine (Ser) in sensitive 
ones [219]. The 631Asn identified mostly in Japanese native chicken breeds screened by Ko et al. [219] 
was associated with enhanced antiviral activity to H5N1 virus in transfected mouse fibroblast 3T3 
cells. Conversely, results obtained by Benfield et al. [232,233] and Schusser et al. [234] indicated that 
neither the 631Asn nor the 631Ser genotypes of chicken Mx1 was able to confer protection against 
several LPAIV and HPAIV including H5N1 subtype in chicken embryo fibroblasts or ECE. Similarly, 
Mx1 631Asn had no effect on viral replication after in-vitro infection of chicken embryo kidney cells 
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with an LPAIV H5N9 [231]. Moreover, transfected chicken cells expressing chicken Mx protein did 
not induce resistance to HPAIV H7N7 [235]. In-vivo, following intranasal infection with an HPAIV 
H5N2, chickens carry Asn631 allele showed delayed mortality, milder morbidity and lesser virus 
excretion than 631Ser homozygotes [231]. Conversely, no correlation was observed between Mx-631 
genotypes and susceptibility of chickens to an HPAIV H7N1 as indicated by clinical status and time 
course of infection [205]. Although, one out of six chicken lines infected with an HPAIV H7N1 had 
lower mortality, the Mx gene was not involved in this variations among tested chicken lines [236]. 
Additionally, chickens carry the homozygous Mx resistant allele genotype augmented the lowest HI 
titer after vaccination with an inactivated H5N2 vaccine compared with chickens that carry the 
sensitive allele [237]. 
Taken together, resistance or susceptibility to a disease is usually multifactorial in nature and 
greatly influenced by both the host and the virus, therefore the role of Mx1 gene merits more in-depth 
investigation [224,234]. In-vivo comparative studies using several native breeds from different 
countries are required to elucidate the role of Mx1 gene in AIV resistance [231].  
3.3.1.2. Other Candidate Genes 
Apart from the Mx1 gene, resistance or less susceptibility of ducks to AIV infections compared 
with chickens has been linked to an influenza virus sensor known as retinoic acid-inducible gene I 
“RIG-I” (a cytoplasmic RNA sensor contribute to AIV detection and IFN production) which is absent 
in chickens [238–240]. This RIG-I gene as a natural AIV resistance gene in ducks could be a 
promising candidate for creation of transgenic chickens [238]. Moreover, different genes and cytokines 
have been expressed after infection of chicken and duck cells with several AIV subtypes including 
HPAIV H5N1 [241–244]. Additional genetic candidates that contribute to inhibition of AIV 
replication could be useful in creation of genetically modified chickens such as cyclophilin A [245], 
ISG15 [246], viperin [247], heat shock cognate protein 70 (Hsc70) [248] or Ebp1 and/or ErbB3-binding 
protein [249]. 
3.3.2. Transgenic Chickens 
Current advance in molecular biology and genetic manipulation can facilitate the development of 
influenza-resistant poultry. Increase resistance of cell lines to influenza virus infection using RNA 
interfering (RNAi) molecules expressed by a lentiviral vector is more efficient transgenic tool than 
direct DNA injection or oncoretroviral vectors infection [10,250,251]. Recently, creation of AIV 
built-in resistant chickens by genetic modification has been experimentally proven by Lyall and 
colleagues [252]. Chickens equipped with a short-hairpin RNA targets the AIV polymerase binding 
sites have been created and infected with HPAIV H5N1. Although all infected transgenic birds 
succumbed to the infection however the virus did not spread to the in-contact transgenic and 
non-transgenic cagemates [252]. Applicability in food production, safety regulations and consumer’s 
preferences are important challenges face development of genetically modified chickens [252,253]. 
Moreover, AIV is a “master of mutability” and global production of the resistant chickens must be 
equipped with many decoys target different genes to avoid rapid generation of AIV resistance. In 
addition, replacement of the commercial flocks with the newly flu-resistant birds is expected to occur 
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within short period due to globalization of the poultry industry however replacement of backyard birds 
seems to be more complicated [253].  
4. Summary and Perspectives 
Epidemics of avian influenza in poultry are a real challenge for the scientific community [12]. 
Recently, several approaches to control the disease were developed and have yielded promising 
results. Although beneficial, these approaches face different limitations and restrictions (Table 1). The 
use of antiviral drugs in poultry could be an ancillary tool to control AIV infections in valuable birds 
but not in commercial sectors. Fears of kicking out our leading antiviral drugs in control of AIV are 
increased by adoption of amantadine (and probably oseltamivir) in poultry and transmission of 
resistant variants to human. On the other hand, limited supply and high costs of oseltamivir preclude 
its widespread use for poultry. Compliance with other medications, adverse effects and drug residues 
in eggs, meat and surrounding environment should be investigated. On the other hand, effectiveness of 
herbal and cytokines-based medications to protect against HPAIV H5N1 should be seriously 
considered and further investigation in-vivo is inevitable. 
Molecular approaches including RNAi and transgenic chickens for control of AIV are encouraging. 
The use of short interfering RNA prevents the replication of AIV seems to be a promising approach; 
however specificity to the viral genome without interference with the host genome and 
non-specifically inhibition of cellular gene activity is critical. Delivery to the host, production costs, 
mass production and application, storage and handling of the final products are important aspects that 
remain unresolved. Possibility for arise of mutants with the ability to evade the siRNA activity should 
also be considered. Genetic resistance to AIV determined by only one point mutation in the Mx gene 
or complex and multigenic host components as recently determined in mice [254] should be firstly 
confirmed and secondly elucidation of its relation to the productivity of birds and other diseases must 
be considered.  
Although a proof-of-principle to produce transgenic chickens has been recently reported, technical, 
logistic and social constraints are facing development of chicken resistant to AIV. Stable transmission 
and expression of the transgene from generation to generation require extensive studies. Regulatory 
approval, mass production, costs and marketing of commercial AIV resistant pedigree lines, consumer 
preferences and food safety issues need to be carefully and fully addressed. Overall, mutation of the 
virus in the face of any control approach remains the real challenge. Influenza epidemics and 
pandemics will likely continue to cause havoc in poultry and human populations, therefore innovative 
alternative or complementary intervention strategies need to be developed. The ultimate goal of 
all control (including alternate) strategies must be the eradication of avian influenza. In this 
context, alternate approaches might be an aid but should not jeopardize surveillance and current  
control measures. 
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Table 1. Advantages and limitations of different alternative approaches for control of avian influenza viruses in poultry. 
Approach  Advantages  Limitations  
Antivirals 
Chemotherapy   
M2 Blockers (Amantadine 
and Rimantadine) and 
Neuraminidase inhibitors 
(Oseltamivir and Zanamivir) 
• Rapid protection 
• Mass administration (feed, water) 
• Cost-effective for individual birds 
(amantadine HCL) 
• Suitable for all types of birds against all 
types of AIV 
• Hazards of kicking out cornerstone antivirals in case of pandemic 
• Emergence of resistant mutants 
• Require long application period to be effective 
• Expensive in flock level (Oseltamivir) 
• Residues in meat and eggs was not fully addressed 
• Compliance with other medical agents need to be considered  
Natural Antivirals   
Herbs 
• Direct antiviral activity 
• Immunoadjuvant effect 
• Additional effects as antioxidants, anti-
inflammatory, etc. 
• No adverse effects on body weight, egg 
production 
• Extraction is very expensive 
• Affection with antigenic changes, herb-drug interactions, 
cytotoxicity and biochemical traits were not fully investigated 
• Extraction methods, preparation, purity of the crude extracts 
greatly influence the efficacy.  
• Batch-to-batch variations are high due to variable plantations 
conditions. 
• Animal models of infection are limited 
Probiotics 
• Direct and indirect antiviral activity 
• Immunoadjuvant effect 
• Dual use as a vaccine-vector and 
immunomodulator 
• Efficacy against AIV particularly HPAIV is still questionable 
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Table 1. Cont. 




• Not affected by antigenic changes 
• Broad spectrum antiviral activities 
• Instability  
• High production costs 
• No mass production 
• Field application limitations  
RNA interference 
• Inhibition of any influenza 
subtype/serotype/variant 
• High specificity to particular 
strain/subtype/variant 
• Do not require intact immune system 
• Use as a prophylactic and/or therapeutic 
• Specificity to the viral genome without interference with the host 
genome and non-specifically inhibition of cellular gene activity is 
critical. 
• Delivery to the host, costs, mass production, storage and handling 
of the final products consider questionable aspects.  
• Possibility for arise of mutants with the ability to evade the siRNA 
activity should not be fully guaranteed 
• Quickly degraded in-vivo 
• Induce a transient & short-term protection and multiple-dose is 
required 
• In-vivo research studies still missing 
Naturally resistant birds 
(Myxovirus Mx resistant 
gene and other candidate 
genes)  
• Few breeds of chickens and ducks can 
survive challenge with HPAIV in nature 
• Results on the contribution of the Mx gene to AIV resistant are 
contradictory 
• Resistant breeds are mostly low producer native breeds. 
• Interrelation of disease-resistance and production should be 
weighed  
• Studies have been conducted only on a limited number of native 
breeds in some countries 
Transgenic birds 
• Although all infected transgenic birds 
succumbed to the infection however the 
virus did not spread to the in-contact 
transgenic and non-transgenic 
cagemates 
• Replacement of backyard flocks 
• Consumer preferences 
• Food safety 
• Regulatory approval  
• Costs of production  
• Mutations of AIV  
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